Surgical Science Sweden AB (SE:SUS)

:SUS

SUS

Surgical Science Sweden AB

RESEARCH TOOLSreports

Want to see SE:SUS full AI Analyst Report?

Surgical Science Sweden AB (SUS) Price & Analysis

5 Followers

SUS Stock Chart & Stats

kr84.50

-kr3.20(-2.25%)

At close: Mar 06 4:00 PM EST

kr84.50

-kr3.20(-2.25%)

Day’s Range― - ―

52-Week Rangekr23.70 - kr162.60

Previous CloseN/A

Volume39.18K

Average Volume (3M)1.61M

Market Cap

kr1.64B

Enterprise Valuekr1.19B

Total Cash (Recent Filing)kr667.73M

Total Debt (Recent Filing)kr2.15M

Price to Earnings (P/E)31.5

Beta0.66

Next Earnings

Aug 19, 2026

EPS Estimate

0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.03

Shares Outstanding51,026,237

10 Day Avg. Volume583,608

30 Day Avg. Volume1,614,194

Financial Highlights & Ratios

PEG Ratio-0.50

Price to Book (P/B)0.39

Price to Sales (P/S)1.67

P/FCF Ratio24.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.97

Revenue Forecast (FY)kr995.98M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetAn exceptionally conservative balance sheet with near-zero leverage and large net cash provides durable financial flexibility. It lowers solvency risk, funds continued product development and the Tel Aviv site, and preserves optionality for capital allocation or M&A even if operating results stay uneven for several quarters.

Consistent Cash Generation & FCF ReboundPositive operating cash flow and a recovered free cash flow profile indicate the business converts earnings into cash sustainably. This supports reinvestment in product launches, production scaling and margin initiatives without relying on external financing, helping the firm execute strategic plans over the next 2–6 months.

Diversifying Product & Robotics PipelineProgress on ultrasound, shared-platform releases and an expanding robotics pipeline reduce dependency on one partner and align with long-term structural adoption of surgical robotics. Broader OEM engagement and new modules support recurring license opportunities and deepen competitive positioning over coming quarters.

Bears Say

Intuitive Commercial Reversion HitA confirmed SEK 60–90m license revenue headwind from the Intuitive commercial reversion is a material, multi-quarter revenue shock. It highlights customer-concentration risk and will pressure reported 2026 top-line and margins, forcing management to rely on diversification and underlying growth to offset lost license income.

High FX Exposure And Currency PressureSignificant USD exposure means currency volatility materially distorts reported revenue and margins. A multi-month USD weakness reduced sales and EBITDA this period; without durable hedges, FX will continue to cause earnings volatility and complicate hitting short-term targets despite underlying operational trends.

Profitability Compression & Regional WeaknessProfitability has compressed versus prior years and trailing revenue is slightly negative, reflecting weaker operating leverage and regional softness (Americas, China). Lower margins and lumpy device/simulator sales increase the time and investment needed to restore historical returns and can restrain sustainable free-cash-flow improvement.

Surgical Science Sweden AB News

Surgical Science Sweden AB Signals Resilient Underlying Growth

Surgical Science Sweden AB (($SE:SUS)) has held its Q1 earnings call. Read on for the main highlights of...

22d ago

Surgical Science Sweden Balances Record Quarter With 2026 Risk

Surgical Science Sweden AB (($SE:SUS)) has held its Q4 earnings call. Read on for the main highlights of...

4M ago

Surgical Science price target lowered to SEK 40 from SEK 120 at Berenberg

Berenberg analyst Simon Jonsson lowered the firm’s price target on Surgical Science (SUSRF) to SEK 40 from SEK...

6M ago

Surgical Science Sweden AB’s Mixed Q3 2025 Earnings Call

Surgical Science Sweden AB (($SE:SUS)) has held its Q3 earnings call. Read on for the main highlights of...

7M ago

SUS

SUS FAQ

What was Surgical Science Sweden AB’s price range in the past 12 months?

Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr162.60 in the past 12 months.

What is Surgical Science Sweden AB’s market cap?

Surgical Science Sweden AB’s market cap is kr1.64B.

When is Surgical Science Sweden AB’s upcoming earnings report date?

Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.

How were Surgical Science Sweden AB’s earnings last quarter?

Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported kr0.37 earnings per share for the quarter, beating the consensus estimate of kr0.305 by kr0.065.

Is Surgical Science Sweden AB overvalued?

According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Surgical Science Sweden AB pay dividends?

Surgical Science Sweden AB does not currently pay dividends.

What is Surgical Science Sweden AB’s EPS estimate?

Surgical Science Sweden AB’s EPS estimate is 0.4.

How many shares outstanding does Surgical Science Sweden AB have?

Surgical Science Sweden AB has 51,026,237 shares outstanding.

What happened to Surgical Science Sweden AB’s price movement after its last earnings report?

Surgical Science Sweden AB reported an EPS of kr0.37 in its last earnings report, beating expectations of kr0.305. Following the earnings report the stock price went up 12.785%.

Which hedge fund is a major shareholder of Surgical Science Sweden AB?

Currently, no hedge funds are holding shares in SE:SUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Surgical Science Sweden AB

Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.